Shield Therapeutics announces Greg Madison to its Board of Directors as CEO

– UK, London –  Shield Therapeutics plc (LON: STX), a commercial-stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer, today announced the appointment of Greg Madison as CEO with effect from 1 June 2021. Greg will be appointed as a Board Director in June 2021.

“I am delighted that Greg will be joining Shield. He brings highly relevant operating experience in growing and leading organisations, as well as deep knowledge in iron deficiency which will be invaluable as we launch and grow Accrufer in the US and extend the commercialisation of Feraccru/Accrufer in other parts of the world. I welcome Greg to Shield and wish him every success. I would also like to thank Tim for his substantial contribution to Shield over the last three years, first as CFO and then as CEO since April 2020. He has played a crucial role in bringing Shield to the point at which Accrufer can be launched in the US.” said  Board Chairman, Hans Peter Hasler.

Tim Watts, Shield’s current CEO, will step down as CEO on 1 June 2021 but will remain with the Group as an Executive Director until 30 September 2021.

About Greg Madison

Greg has an excellent commercialization track record and, in particular, he has deep knowledge and previous experience in the US iron deficiency marketplace.

Greg is a seasoned executive who brings strong operating experience and a track record of success leading small to medium size organisations. Before joining Shield, he was CEO at Melt Pharmaceuticals in Boston, MA, a company developing a sublingual formulation of midazolam and ketamine, providing needle and opioid-free procedural sedation and analgesia. Before Melt Pharmaceuticals, he was CEO of Keryx Biopharmaceuticals from 2015 to 2018, where he led the transformation of the organisation from development stage to commercial stage focused on Auryxia, an oral product for the treatment of hyperphosphatemia and iron deficiency anaemia, and ultimately leading to a merger with Akebia Therapeutics. In 2013 and 2014, he was Chief Commercial Officer at AMAG Pharmaceuticals where he was closely involved with Feraheme, a leading intravenous product for the treatment of iron deficiency. From 2000-2012, Greg was at Genzyme Corporation, ultimately serving as VP and GM of its Nephrology Division, where he led a division that had revenues over $1 billion, led by the world’s leading phosphate binder, Renvela. Greg began his career as a sales representative for Janssen Pharmaceuticals, a division of Johnson and Johnson.

Greg Madison commented: “I am excited to be joining Shield Therapeutics at this point in the Company’s evolution, as we are undertaking final preparations for the launch of Accrufer in the US, and look to accelerate our growth in Europe. Iron deficiency anemia is a significant challenge for patients worldwide, and an oral option like Accrufer that can deliver significant increases in hemoglobin while being well-tolerated by patients provides clinicians and patients a potentially valuable and needed option. I look forward to working with the current team across all of our initiatives.”

About Shield Therapeutics PLC

Shield Therapeutics PLC is a commercial stage, a pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru /Accrufer, a novel, stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Shield’s lead product, Feraccru/Accrufer, has been approved for use in the United States, European Union, UK, and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer in the US during 2021 through a highly experienced sales and marketing team. Feraccru is already being commercialized in the UK and European Union by Norgine B.V., who also have marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Feraccru/Accrufer in China, Hong Kong, Macau, and Taiwan.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.